Physician profile
Gregory Colangelo
NPI 1083674220
$5,491.06
in general payments reported to CMS, 2019-2025
27 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $103 · 2021: $82.13 · 2022: $36.02 · 2023: $63.93 · 2024: $3,987 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,279 · Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,279.17 |
| Food and Beverage | $670.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,997.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $543.89 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $192.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.39 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $81.47 | 2019-2021 | |
| Advanced Respiratory, INC | $41.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.82 | 2020 | |
| Pulmonx Corporation | $39.31 | 2019-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sunovion Pharmaceuticals INC. | $38.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.68 | 2019 | |
| Philips North America LLC | $28.26 | 2019-2021 | |
| Circassia INC. | $26.76 | 2019 | |
| Genzyme Corporation | $24.65 | 2019 | |
| Inspire Medical Systems, INC. | $23.03 | 2024 | Inspire |
| Ethicon INC. | $18.89 | 2023 | Monarch Platform |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.57 | 2019 | |
| Genentech USA, INC. | $18.23 | 2019 | |
| Mylan Specialty L.P. | $17.26 | 2019 | |
| Becton, Dickinson and Company | $16.66 | 2025 | Hemosphere |
| Paratek Pharmaceuticals, INC. | $16.43 | 2019 | |
| Breathe Technologies, INC. | $16.05 | 2019 | |
| Csl Behring | $15.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.90 | 2019 | |
| Abbvie INC. | $14.74 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.70 | 2019 | |
| Insmed, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Colangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.